Table 5.
Outcome | Covariate* | Incidence Rate Ratio | 95% Conf. Interval | P** |
---|---|---|---|---|
Prospective ACS§ | Gender (female) | 1.54 | (0.94, 2.53) | 0.089 |
ACS episode before age 4 | 2.56 | (1.59, 4.12) | <0.001 | |
Wheezing caused shortness of breath | 1.78 | (1.02, 3.09) | 0.042 | |
Wheezing after exercise | 1.31 | (0.78, 2.22) | 0.312 | |
Two or more positive skin tests | 1.87 | (1.16, 3.00) | 0.010 | |
FEV1/FVC <LLN | 0.86 | (0.48, 1.53) | 0.606 | |
Bronchodilator response ≥ 12% | 1.18 | (0.66, 2.11) | 0.581 | |
Prospective Pain§ | Age of first contact | 1.05 | (0.99, 1.12) | 0.116 |
Hemoglobin (g/dl)# | 1.32 | (1.09, 1.60) | 0.004 | |
Mother has asthma | 1.50 | (0.73, 3.09) | 0.273 | |
Two or more positive skin tests | 1.14 | 0.68, 1.92) | 0.628 | |
FEV1/FVC <LLN | 0.76 | (0.42, 1.39) | 0.377 | |
Bronchodilator response ≥ 12% | 0.89 | (0.48, 1.66) | 0.720 |
Negative Binomial regression model with adjustment for over dispersion. Two-tailed significance values.
130 patients with non-missing data in SAC cohort with skin tests, bronchodilator response, and lower airway obstruction, defined as the forced expired volume in 1 second/forced vital capacity (FEV1/FVC) < lower limit of normal (LLN) according these equations provided by Quanjer et al.14